Biased antagonism of a series of bicyclic CXCR2 intracellular allosteric modulators.

Front Pharmacol · 2025 · PMC12301332 · PMID 40727104

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Additionally, MVH3 is nonsignificantly different from navarixin for CXCL2, CXCL5, and CXCL6 responses while being highly significant for CXCL1-induced responses.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.